BIOXCEL THERAPEUTICS, INC.

BTAI · NASDAQ

Pharmaceutical Preparation Manufacturing · United States

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

Market Data

Price $1.56 -0.17 (-9.83%)

Market Cap$38M

P/E Ratio—

EPS$—

52W High$8.08

52W Low$1.17

Beta0.33

Data from Finnhub · Updated Mar 10, 2026